サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1728083

片頭痛治療薬市場- 世界の産業規模、シェア、動向、機会、予測、治療薬別、投与経路別、流通経路別、地域別、競合別、2020-2030年

Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutics, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

片頭痛治療薬市場- 世界の産業規模、シェア、動向、機会、予測、治療薬別、投与経路別、流通経路別、地域別、競合別、2020-2030年
出版日: 2025年05月16日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

片頭痛治療薬の世界市場規模は2024年に38億9,000万米ドル、予測期間中のCAGRは4.31%で、2030年には50億1,000万米ドルに達すると予測されます。

この市場は、片頭痛の罹患率の上昇、患者の意識の高まり、薬剤開発の急速な進歩により、着実に拡大しています。片頭痛は慢性的な神経疾患であり、世界的に多くの患者が罹患しているため、効果的な治療オプションに対する強い需要が生じています。カルシトニン遺伝子関連ペプチド（CGRP）阻害薬やゲパントといった現在進行中の技術革新に支えられ、より的を絞った個別化治療への顕著なシフトが起こっており、これらは有望な臨床結果を示しています。片頭痛が公衆衛生や経済に与える影響に対する認識の高まりも、官民両部門による研究開発への投資を後押ししています。製薬会社は次世代医薬品や生物製剤の導入に注力しており、市場はより効果的で個別化された治療戦略に向けて進化を続けています。こうした技術革新は、ヘルスケアに対する意識の高まりやアクセスの改善とともに、市場の持続的成長を支えるものと期待されます。

市場概要
予測期間 2026-2030
市場規模：2024年 38億9,000万米ドル
市場規模：2030年 50億1,000万米ドル
CAGR：2025年～2030年 4.31%
急成長セグメント 鎮痛薬
最大市場 北米

市場促進要因

片頭痛の高い有病率

主な市場課題

医薬品開発の複雑さ

主な市場動向

精密医療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 臨床試験分析

第5章 顧客の声

第6章 世界の片頭痛治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療薬別{鎮痛薬（鎮痛剤、トリプタン、麦角アルカロイド、その他）、予防薬（血圧降下薬、抗けいれん薬、カルシトニン遺伝子関連ペプチド（CGRP）拮抗薬、その他の予防療法）}
    • 投与経路別（経口・経鼻、注射剤）
    • 流通チャネル別（小売薬局、病院薬局、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第7章 北米の片頭痛治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州の片頭痛治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第9章 アジア太平洋地域の片頭痛治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米の片頭痛治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカの片頭痛治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

  • 最近の動向
  • 合併と買収

第14章 世界の片頭痛治療薬市場：SWOT分析

第15章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替治療法の脅威

第16章 競合情勢

  • Amgen Inc.
  • Teva Pharmaceutical Industries Limited
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Bausch Health Companies Inc.
  • Novartis AG
  • AbbVie Inc.
  • Lundbeck Inc
  • Dr. Reddy's Laboratories Limited
  • Impel Pharmaceuticals Inc

第17章 戦略的提言

第18章 調査会社について・免責事項

目次
Product Code: 16304

The Global Migraine Therapeutics Market was valued at USD 3.89 Billion in 2024 and is projected to reach USD 5.01 Billion by 2030, growing at a CAGR of 4.31% during the forecast period. This market is expanding steadily due to the rising incidence of migraine, growing patient awareness, and rapid advancements in drug development. Migraine, a chronic neurological condition, affects a significant global population, leading to strong demand for effective treatment options. A notable shift is occurring toward more targeted and individualized therapies, supported by ongoing innovations such as calcitonin gene-related peptide (CGRP) inhibitors and gepants, which are demonstrating promising clinical outcomes. Increased recognition of migraine's public health and economic impacts has also driven investment in R&D by both public and private sectors. With pharmaceutical companies focusing on introducing next-generation drugs and biologics, the market continues to evolve toward more effective and personalized treatment strategies. These innovations, along with greater awareness and improved access to healthcare, are expected to support sustained market growth.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.89 Billion
Market Size 2030USD 5.01 Billion
CAGR 2025-20304.31%
Fastest Growing SegmentPain-Relieving Medications
Largest MarketNorth America

Key Market Drivers

High Prevalence of Migraine

The widespread occurrence of migraine is a key driver fueling the growth of the Migraine Therapeutics Market. Migraine affects individuals of all ages, genders, and demographics, making it a pervasive public health issue. The condition is a leading cause of disability and contributes to significant losses in productivity, impacting both individuals and economies. As per a March 2024 WHO report, around 40% of the global population-approximately 3.1 billion people-suffered from migraines and other headache disorders as of 2021. The condition shows a higher prevalence among women, likely due to hormonal factors. Migraine ranks among the top three neurological disorders from childhood through late adulthood. This widespread burden has led to increased attention from healthcare stakeholders, driving awareness, diagnosis, and treatment. The rising recognition of migraine's impact on quality of life has also encouraged the development and uptake of more effective therapies, including CGRP inhibitors and gepants, further expanding the market.

Key Market Challenges

Drug Development Complexity

Developing effective migraine therapeutics presents significant challenges due to the complex nature of the condition. Migraine manifests with diverse symptoms and triggers, requiring a deep understanding of its neurological basis for effective drug design. Identifying precise molecular targets is difficult, as the underlying mechanisms of migraine are still not fully understood. The clinical trial process for migraine treatments can be lengthy and costly, involving large patient populations and extended follow-up periods. Subjective symptom reporting and placebo responses add further complexity. Regulatory agencies such as the FDA require comprehensive evidence of safety and efficacy, necessitating rigorous testing and data collection. In addition, evolving clinical trial endpoints demand constant adaptation from researchers and sponsors. These challenges, combined with high development costs, can delay innovation and restrict market entry, particularly for smaller firms.

Key Market Trends

Precision Medicine

Precision medicine is emerging as a transformative trend in the Migraine Therapeutics Market, offering more effective and individualized treatment strategies. By utilizing genetic, molecular, and clinical data, precision medicine allows for the customization of therapies based on a patient's unique migraine profile. Advances in genetic testing and biomarker analysis enable pharmaceutical developers and healthcare providers to better identify subgroups of patients who are most likely to benefit from specific treatments. This targeted approach improves treatment outcomes, reduces side effects, and enhances patient satisfaction. For pharmaceutical companies, precision medicine increases the efficiency of drug development and can lead to faster regulatory approvals. It also offers the potential for higher market differentiation and pricing power. As demand grows for more personalized healthcare solutions, the integration of precision medicine into migraine treatment protocols is expected to expand significantly, reshaping the market landscape and improving therapeutic success rates.

Key Market Players

  • Amgen Inc.
  • Teva Pharmaceutical Industries Limited
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Bausch Health Companies Inc.
  • Novartis AG
  • AbbVie Inc.
  • Lundbeck Inc
  • Dr. Reddy's Laboratories Limited
  • Impel Pharmaceuticals Inc

Report Scope:

In this report, the Migraine Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Migraine Therapeutics Market, Therapeutics:

  • Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others)
  • Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)

Migraine Therapeutics Market, Route of Administration:

  • Oral & Nasal
  • Injectables

Migraine Therapeutics Market, Distribution Channel:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Others

Migraine Therapeutics Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Migraine Therapeutics Market.

Available Customizations:

Migraine Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

  • 4.1. Ongoing Clinical Trials
  • 4.2. Completed Clinical Trials
  • 4.3. Terminated Clinical Trials
  • 4.4. Breakdown of Pipeline, By Development Phase
  • 4.5. Breakdown of Pipeline, By Status
  • 4.6. Breakdown of Pipeline, By Therapeutic Area
  • 4.7. Breakdown of Pipeline. By Region
  • 4.8. Clinical Trials Heat Map

5. Voice of Customer

6. Global Migraine Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutics {Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others), and Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)}
    • 6.2.2. By Route of Administration (Oral & Nasal, Injectables)
    • 6.2.3. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2024)
  • 6.3. Market Map

7. North America Migraine Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutics
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Migraine Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutics
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Canada Migraine Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutics
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Mexico Migraine Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutics
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel

8. Europe Migraine Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutics
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Migraine Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutics
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. United Kingdom Migraine Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutics
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Italy Migraine Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutics
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. France Migraine Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutics
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Spain Migraine Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutics
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Migraine Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutics
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Migraine Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutics
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. India Migraine Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutics
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Japan Migraine Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutics
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. South Korea Migraine Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapeutics
        • 9.3.4.2.2. By Route of Administration
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Australia Migraine Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapeutics
        • 9.3.5.2.2. By Route of Administration
        • 9.3.5.2.3. By Distribution Channel

10. South America Migraine Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutics
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Migraine Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutics
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Argentina Migraine Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutics
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Colombia Migraine Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutics
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Migraine Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapeutics
    • 11.2.2. By Route of Administration
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Migraine Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapeutics
        • 11.3.1.2.2. By Route of Administration
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Saudi Arabia Migraine Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapeutics
        • 11.3.2.2.2. By Route of Administration
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. UAE Migraine Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapeutics
        • 11.3.3.2.2. By Route of Administration
        • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Development
  • 13.2. Mergers & Acquisitions

14. Global Migraine Therapeutics Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Treatment Types

16. Competitive Landscape

  • 16.1. Amgen Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Teva Pharmaceutical Industries Limited
  • 16.3. GlaxoSmithKline plc
  • 16.4. Eli Lilly and Company
  • 16.5. Bausch Health Companies Inc.
  • 16.6. Novartis AG
  • 16.7. AbbVie Inc.
  • 16.8. Lundbeck Inc
  • 16.9. Dr. Reddy's Laboratories Limited
  • 16.10. Impel Pharmaceuticals Inc

17. Strategic Recommendations

18. About Us & Disclaimer